Dr. Angel Cequier, clinical director for heart disease in Bellvitge University Hospital, is one of the authors of the article Thromb-Receptor Antagonist in Acute Coronary Syndrom Vorapaxar ,  published on November 13th in The New England Journal of Medicine .

Dr. Cequier is one of the authors of the article on a new antiplatelet published in The New England Journal of Medicine

The study, conducted by the multinational group of researchers TRACER ( Thromb Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome ), was the first major test of a new antiplatelet, vorapaxar. Dr. Cequier was the national coordinator in Spain and member of the Steering Committee of the study.

Specifically, the work has compared this drug with placebo in a total of 12,944 patients with acute coronary syndromes from centers of  37 countries.

The results have revealed, contrary to expectations, that the new drug does not reduce significantly the risk of a number of events analyzed jointly, such as cardiovascular mortality, myocardial infarction, stroke, the cerebrovascular accident, the recurrent ischemia, or urgent coronary revascularization, although it significantly reduces the incidence of myocardial infarction. It has also shown that patients taking the drug have a significantly higher risk of bleeding. The track ended early after a security review.

January 2012

Notícies relacionades |Noticias relacionadas | Related news

Comments are closed.

Home | eHub | Email